Abbott Laboratories and Bigfoot Biomedical have partnered to develop diabetes management systems by integrating Abbott’s FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions.
"Diabetes is increasing at record rates globally," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "There is a significant demand for tools that are intuitive and easy to use to help people take control of this complicated, challenging condition, but innovation in this area has been slow. Together with Bigfoot, we are challenging conventional methods of diabetes management by bringing together our expertise in superior glucose monitoring technology with a best-in-class insulin delivery system that is designed with the patient in mind. This will fundamentally transform the way diabetes is managed."
Using personalized technology and delivery, the platform is able to increase accessibility while lowering the cost to both the patient and provider.
"Bigfoot is committed to solving the hard problems inherent in blending consumer technology, enterprise systems and Class III medical devices in an effort to design an easy-to-use system for people with diabetes," said Jeffrey Brewer, Bigfoot Biomedical president and CEO. "Both Abbott and Bigfoot understand the real-world use of diabetes devices. A no-calibration glucose sensor is the final piece of the puzzle needed to enable consumer-friendly and accessible integrated insulin delivery systems."